RDIF offered Pfizer to test Sputnik Light as a third dose

The Russian Direct Investment Fund (RDIF) has offered Pfizer to conduct clinical trials of the Sputnik Light coronavirus vaccine as a third dose to combat the spread of the coronavirus delta strain, according to the Sputnik V Twitter page.

"The rise in delta strains in the US and Israel shows that mRNA vaccines need a heterogeneous booster to enhance and prolong the immune response," the report said.

It notes that Sputnik V is 83.1% effective against the delta strain of coronavirus. “Today, RDIF is proposing that Pfizer begin research on Sputnik Light as a booster,” the vaccine tweeted.

In July, RDIF announced the preliminary results of trials of a combination of Sputnik V and AstraZeneca vaccines to combat coronavirus strains. Fifty volunteers were vaccinated and did not experience any "serious adverse events," the foundation said.